

HTA - - Health Technology Assessment Report

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

Code: PM36842446

Year: 2023 **Date:** 2014

Author: Uluer AZ

Study design (if review, criteria of inclusion for studies)

HTA report

Interventions

Ivacaftor (Kalydeco)

[http://dx.doi.org/10.1016/S2213-2600\(22\)00504-5](http://dx.doi.org/10.1016/S2213-2600(22)00504-5)

See also

Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23.

Keywords

Aminophenols; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; VX-770; ivacaftor;